Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

· Issued by Ligand Pharmaceuticals Incorporated via GlobeNewswire

Summary by 6ix AI

Ligand Pharmaceuticals Incorporated, which partners with biopharmaceutical companies to finance drug development in exchange for royalties, will report its second quarter 2026 financial results on Thursday, August 6, 2026.

Key details

  • Ligand will hold a conference call beginning at 8:30 a.m. Eastern time on August 6, 2026 to discuss the results and give a general business update.
  • Dial-in numbers are +1 (585) 542-9983 (US local) and +1 (833) 461-5787 (US toll-free), meeting ID 780702347; live and replay webcasts of the call will be available.

6ix AI wrote this summary from the release below and checked it against the release.

JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.

Conference Call and Webcast Information

Date:

Thursday, August 6, 2026

Time:

8:30 a.m. Eastern time

Conference Call:

United States (Local): +1 (585) 542-9983

United States (Toll-Free): +1 (833) 461-5787

International: Global Dial-in Numbers

Meeting ID: 780702347

Webcast:

Live and replay webcasts of the call are available here.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand's royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Contacts

Investors:
Melanie Herman
[email protected]
(858) 550-7761

Media:
Kellie Walsh
[email protected]
(914) 315-6072

Ligand Pharmaceuticals Incorporated on 6ix

Story so far

Earlier from Ligand Pharmaceuticals

Later from Ligand Pharmaceuticals

All Ligand Pharmaceuticals news releases